Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Sinopharm Group Signs Three-Year Supply Purchase Agreement With CNPGC

By Public Technologies
  • Sinopharm Group signed five framework agreements on Nov. 9, 2026, covering procurement, sales, construction contracting, factoring and financial services.
  • The agreements run from Jan. 1, 2027, through Dec. 31, 2029; procurement and financial services agreements require independent shareholder approval.
  • Proposed annual transaction caps with CNPGC are RMB 7.2 billion for procurement and RMB 2 billion for sales throughout the term.
  • Construction contracting caps rise from RMB 790 million in 2027 to RMB 915 million in 2028 and RMB 1.07 billion in 2029.
  • The proposed maximum daily deposit balance, including accrued interest, increases to RMB 5 billion from RMB 2.63 billion under the existing agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12406173), on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.